Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00147901
Status:
COMPLETED
Last Update Posted:
2016-10-03
First Post:
2005-09-02
Brief Title:
Fludarabine Cyclophosphamide and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia B-CLL
Sponsor:
German CLL Study Group
Organization:
German CLL Study Group
Study Overview
Official Title:
Multicenter Phase II Trial of Fludarabine and Cyclophosphamide in Combination With Alemtuzumab FC-Cam for Patients With Relapsed Chronic Lymphocytic Leukemia - CLL-2L Protocol of the German CLL-Study Group GCLLSG
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to assess the short term efficacy of a combination immunochemotherapy in patients with relapsed B-cell chronic lymphatic leukemia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-003017-32 | EUDRACT_NUMBER | None | None |